The clinical approach toward giant cell tumor of bone

…, MAJ van de Sande, JR Kroep, RA Nout… - The …, 2014 - academic.oup.com
We provide an overview of imaging, histopathology, genetics, and multidisciplinary
treatment of giant cell tumor of bone (GCTB), an intermediate, locally aggressive but rarely …

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

…, D Lorusso, C Marth, P Morice, RA Nout… - International Journal of …, 2021 - ijgc.bmj.com
A European consensus conference on endometrial carcinoma was held in 2014 to produce
multi-disciplinary evidence-based guidelines on selected questions. Given the large body of …

[HTML][HTML] Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival

…, W Pondaag, H Gelderblom, RA Nout… - European Spine …, 2018 - Springer
Background and aims The aim of this systematic review is to describe the epidemiology of
chordoma and to provide a clear overview of clinical prognostic factors predicting …

Uterine serous carcinoma

…, T Enomoto, K Takehara, H Denys, RA Nout… - Gynecologic …, 2021 - Elsevier
Serous endometrial cancer represents a relative rare entity accounting for about 10% of all
diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related …

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non …

RA Nout, V Smit, H Putter, IM Juergenliemk-Schulz… - The Lancet, 2010 - thelancet.com
Background After surgery for intermediate-risk endometrial carcinoma, the vagina is the
most frequent site of recurrence. This study established whether vaginal brachytherapy …

[HTML][HTML] Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy

…, EJ Crosbie, M De Bruyn, RA Nout… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …

MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

…, E Van Limbergen, BR Pieters, LT Tan, RA Nout… - The Lancet …, 2021 - thelancet.com
Background The concept of the use of MRI for image-guided adaptive brachytherapy
(IGABT) in locally advanced cervical cancer was introduced 20 years ago. Here, we report …

Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts

E Stelloo, RA Nout, EM Osse, IJ Jürgenliemk-Schulz… - Clinical cancer …, 2016 - AACR
Purpose: Recommendations for adjuvant treatment for women with early-stage endometrial
carcinoma are based on clinicopathologic features. Comprehensive genomic …

[HTML][HTML] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label …

…, VT Smit, N Singh, V Do, R D'Amico, RA Nout… - The lancet …, 2018 - thelancet.com
Background Although women with endometrial cancer generally have a favourable
prognosis, those with high-risk disease features are at increased risk of recurrence. The …

[HTML][HTML] Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

E Stelloo, T Bosse, RA Nout, HJ MacKay… - Modern …, 2015 - nature.com
This study aimed to investigate whether molecular analysis can be used to refine risk
assessment, direct adjuvant therapy, and identify actionable alterations in high-risk …